Article Text

Download PDFPDF

Angiotensin converting enzyme inhibition: from viper to patient
  1. Michel Komajda,
  2. Marie-Catherine Wimart
  1. Service de Cardiologie, Hôpital Pitié-Salpétrière, 47-83 Boulevard de l'hôpital, 75651 Paris Cedex 13, France
  1. Professor Komajda

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The story of angiotensin converting enzyme (ACE) inhibitors started approximately 50 years ago, when it was discovered that human plasma incubated with the venom of the Brazilian viper,Bothrops Jararaca, generated a hypotensive compound. This discovery quickly led to the characterisation of the active principle of the venom by Fereira and Greene as a family of peptides, which were named bradykinin potentiating factors as they selectively improved the biological effects of bradykinin. The observation was then made by Vane that these peptides could also block the conversion of angiotensin I into angiotensin II via the angiotensin converting enzyme. The active peptides were isolated and teprotide became the first ACE inhibitor to be evaluated clinically. The search for an orally active compound that was sufficiently potent to be developed as an antihypertensive drug resulted in the design and development of captopril, which entered first phase clinical studies in 1977.

ACE has a key role in two different physiological pathways (fig 1). One is in the synthesis of angiotensin II, which has vasoconstrictive properties, promotes retention of sodium and water, and promotes cell growth. The second is in the breakdown of bradykinin into inactive peptides. Bradykinin is a potent vasodilator through the synthesis of nitric oxide and vasodilatory prostaglandins. Importantly, alternative pathways exist such as the kinase pathway, which bypass ACE in the generation of angiotensin II. Also, the renin-angiotensin system (RAS) is not only found in the circulation, but also in tissues. All components of the cascade are found in a series of tissues, including the heart and the vascular wall.

Figure 1

Role of ACE inhibitors in the renin-angiotensin aldosterone system.

With the widespread actions of RAS, it is not surprising that many potential beneficial effects have been ascribed to ACE inhibitors including improvement of endothelial function, an antihypertensive effect, and a reduction in left ventricular mass. There are currently 11 different ACE inhibitors available and, interestingly, there are still a further five molecules under investigation. These agents differ considerably in terms of their pharmacological properties (table1).

Table 1

ACE inhibitor pharmacological properties

ACE inhibitors can be used in the following areas:

  • hypertension;

  • heart failure/asymptomatic left ventricular dysfunction;

  • acute/post-myocardial infarction;

  • diabetic complications, including nephropathy and retinopathy;

  • non-diabetic nephropathy.

It is very likely that, following the results of the HOPE study, a new indication for coronary or vascular primary prevention in high risk patients will be introduced.1


Hypertension was the original indication for ACE inhibitors. Two key studies have recently been published which examine the role of ACE inhibitors in hypertension: UKPDS and CAPPP.2 3 In UKPDS, patients with type II diabetes and concomitant hypertension were randomised either to very active antihypertensive treatment (with captopril or atenolol) or to a less stringent management strategy. Active care produced a significant decrease in both micro- and macrovascular events in this population.2

The CAPPP trial enrolled more than 10 000 patients and studied the effect of captopril compared to more traditional strategies (β blockers and diuretics). The two strategies were equivalent on the composite end point of fatal and non-fatal myocardial infarction, stroke, and other cardiovascular deaths. There was a significant increase in the risk of stroke in the captopril group, although overall cardiovascular mortality favoured captopril.3 The recently completed STOP-Hypertension-2 study provides further evidence of the role of ACE inhibitors in the treatment of hypertension.4In addition, ALLHAT, a large, ongoing trial which includes over 40 000 patients, will evaluate the difference between various therapeutic strategies on composite cardiovascular end points in hypertensive patients.5

Importantly, it has been shown that left ventricular hypertrophy (LVH) is an independent predictor of mortality; therefore one of the major goals of current antihypertensive treatments is to reduce LVH. In a recent meta-analysis it was shown that ACE inhibition produced a 15% reduction in left ventricular mass, which was greater than that achieved by three other antihypertensive classes investigated in the analysis.6

Heart failure

A wide spectrum of heart failure patients, from New York Heart Association (NYHA) functional class II to IV, benefit from ACE inhibitor treatment. A number of studies have demonstrated a reduction in mortality in patients treated with ACE inhibitors: CONSENSUS 1 (40% reduction); SOLVD treatment (16% reduction); V-HeFT II (28% reduction).7-9 Moreover, it was shown in the ATLAS trial that there was a non-significant trend towards reduced mortality with high dose lisinopril when compared with patients taking a low dose (fig2). The SOLVD-treatment, ATLAS, and SAVE trials have also shown that ACE inhibitors are able to reduce the hospitalisation rate of heart failure patients by a significant 20–25%.8 10 11

Figure 2

There is an early divergence between the two curves in favour of the ACE inhibitor in (A) CONSENSUS 1 (heart failure mortality), (B) SOLVD (mortality caused by progressive heart failure), and (C) ATLAS (all cause mortality plus hospitalisation for any reason).

Myocardial infarction

There are two subsets of myocardial infarction patients who benefit from ACE inhibitors: acute myocardial infarction patients and post-myocardial infarction patients who have signs of cardiac damage. In the ISIS-4 study, use of ACE inhibitors in patients with acute myocardial infarction resulted in a 7% mortality reduction at five weeks and in the GISSI-3 study, an 11% reduction at six weeks.12 13

ACE inhibitors also demonstrate benefits in post-myocardial infarction patients who have either left ventricular dysfunction (SAVE) or overt heart failure (AIRE). Data from the SAVE trial, among patients with left ventricular dysfunction after an acute myocardial infarction, demonstrate a reduction in mortality from cardiovascular causes of 21% with ACE inhibitor treatment.11

Diabetic nephropathy

ACE inhibitors have been demonstrated to be beneficial in diabetic nephropathy in at least two studies. In the study by Lewis and colleagues, a combined end point of death and need for dialysis or transplantation was reduced by 50% in high risk patients with type 1 diabetes.14 In the EUCLID study, using lisinopril in normotensive type 1 diabetic patients, there was a 20% reduction in urinary albumin excretion.15

Non-diabetic nephropathy

ACE inhibitors have also been demonstrated to prevent the progression of renal insufficiency in patients without diabetes. Two studies (with benazepril and ramipril) have each demonstrated a very impressive reduction in the risk of progressive renal insufficiency of more than 50%.16 17 In one of the studies, the beneficial effect was observed even after correction for blood pressure. This suggests that the nephroprotective effect of ACE inhibitors might be independent of the hypotensive effect.

Diabetic retinopathy

In diabetic retinopathy, ACE inhibitors have also been shown to decrease the progression of the disease, both in type 1 and type 2 diabetic patients. In the EUCLID study, lisinopril reduced the risk of retinopathy progression by one grade by 50% (p = 0.02), and in the UKPDS the outcome was reduced by 37%.2 18

Unanswered questions

Despite the wealth of evidence that exists for the efficacy of ACE inhibitors in the management of a range of conditions, there remain unanswered questions.

For example, there are interesting experimental data suggesting that, at least for the regression of left ventricular hypertrophy, the inhibition of bradykinin breakdown may be important. However, there are very little clinical data available, so this question remains open. Moreover, there are contradictory results in the literature regarding the importance of the escape pathway. An in vitro study showed that kinase-like enzyme activity was predominant over ACE activity in both the heart and the aorta.19 Conversely, in an in vivo study in normotensive subjects the administration of enalapril was able to inhibit the pressure response to angiotensin I intravenous infusion, and to block totally the conversion of angiotensin I into angiotensin II.20 Therefore, the clinical importance of the escape pathway is not yet fully understood.

Trial acronyms

ALLHAT: Antihypertensive and Lipid Lowering to prevent Heart Attack Trial
ATLAS: Assessment of Treatment with Lisinopril and Survival
CAPPP: Captopril Prevention Project
CHARM: Candesartan in Heart failure— Assessment of Reduction in Mortality and morbidity
CONSENSUS-1: Co-Operative North Scandinavian Enalapril Survival Study
ELITE II: Evaluation of Losartan In The Elderly-2
EUCLID: EUrodiab Controlled trial of Lisinopril in Insulin dependent Diabetes mellitus
GISSI-3: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto miocardico
HOPE: Heart Outcomes Prevention Evaluation
ISIS-4: Fourth International Study of Infarct Survival
SAVE: Survival And Ventricular Enlargement
SOLVD: Studies Of Left Ventricular Dysfunction
STOP-Hypertension-2: Swedish Trial in Old Patients with Hypertension-2 study
UKPDS: UK Prospective Diabetes Study
V-HeFT II: Vasodilator Heart Failure Trial II

Interest has also recently focused on whether better responders to ACE inhibitors can be identified. Probably, the black population are not suitable patients for antihypertensive treatment with ACE inhibitors. The diabetic population, by contrast, benefits greatly from ACE inhibitor treatment. In the CAPPP study ACE inhibition was able to reduce the occurrence of cardiovascular events by more than 40% in the diabetic patient.3 In the GISSI-3 trial there was a threefold reduction in mortality in diabetic patients as opposed to the total population.10

A potential new avenue for identifying suitable patients is the use of pharmacogenetics. It is possible that, in the future, the identification of new polymorphisms will allow the selection of better responders to ACE inhibitors. For example, the D/D genotype is associated with a greater elevation of blood pressure following angiotensin I intravenous infusion and a greater response to intravenous enalaprilat. This genotype is also associated with higher levels of cardiac ACE activity.

The future

There is much speculation as to whether angiotensin II receptor blockers will challenge ACE inhibitors in the treatment of hypertension. Following the results of the ELITE II trial, ACE inhibition remains the gold standard as first line treatment for heart failure.21 There is also interest in possible new indications for ACE inhibitors. Ongoing trials are assessing whether ACE inhibitors are beneficial in high risk patients. This may result in a new indication of cardiovascular prevention in these high risk populations. Another important issue is whether the combination of ACE inhibition with AT1 blockade has benefits. There is an ongoing trial programme, CHARM, which compares the combination of candesartan and enalapril to enalapril alone in patients with heart failure.22 Another potential new avenue is the development of dual inhibitors which block both ACE and the neutral endopeptidase. With such strong evidence demonstrating the benefits of ACE inhibition it is very disappointing that there is still under use of this class of medication in clinical practice.